CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Last trade$1.94
Day change-$0.045 (-2.27%)
Day range$1.93 – $2.10
Volume1,389,509
Market cap$433M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$433.83M
Price / earnings
—
Price / book
1.52×
Price / sales
30.93×
EV / sales
28.51×
EV / EBITDA
-4.27×
Profitability
Earnings per share
-$0.41
Return on assets
-24.25%
Return on equity
-31.04%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.82×
Quick ratio
7.82×
Cash ratio
0.75×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CTMX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.69M
$1.42M
$10.26M
$663K
$5.96M
$18.66M
$50.92M
$38.09M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.69M
$1.42M
$10.26M
$663K
$5.96M
$18.66M
$50.92M
$38.09M
Selling, general and administrative
$8.71M
$7.6M
$10.69M
$7.36M
$6.43M
$6.62M
$9.43M
$5.62M
Research and development
$16.48M
$17.6M
$19.24M
$21.24M
$15.3M
$13.32M
$18.87M
$14.79M
Total operating expenses
$25.19M
$25.2M
$29.93M
$28.6M
$21.73M
$19.94M
$28.3M
$20.41M
Operating income
-$23.5M
-$23.78M
-$19.67M
-$27.93M
-$15.77M
-$1.29M
$22.62M
$17.68M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$19.94M
-$20.61M
-$18.19M
-$26.46M
-$14.17M
-$91K
$23.59M
$18.94M
Income taxes
$61K
$60K
$59K
$54K
$58K
$63K
$62K
$62K
Net income
-$20M
-$20.67M
-$18.25M
-$26.51M
-$14.23M
-$154K
$23.53M
$18.88M
Net income attributable to common shareholders
-$20M
-$20.67M
-$18.25M
-$29.51M
-$14.23M
-$154K
$23.53M
$18.88M
EBITDA
-$23.09M
-$23.73M
-$19.42M
-$27.42M
-$15.63M
-$939K
$23.01M
$18.09M
Basic earnings per share
-$0.09
-$0.09
-$0.10
-$0.17
-$0.09
$0.00
$0.27
$0.22
Diluted earnings per share
-$0.09
-$0.09
-$0.10
-$0.17
-$0.09
$0.00
$0.27
$0.22
Recent news
Company coverage with links to the original publishers.
CytomX Therapeutics reported a quarterly loss of $0.09 per share matching consensus estimates, but revenues of $1.69 million missed expectations by 59.68%, down significantly from $5.96 million year-ago. The stock has declined 44.8% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.
CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.
CytomX Therapeutics expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies combining CytomX's PROBODY platform with Regeneron's Veloci-Bi platform. CytomX will receive $37 million for two additional programs, with potential total milestones reaching approximately $4 billion across up to 6 additional future targets.
CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.
The article compares small-cap and megacap healthcare stocks, using CytomX Therapeutics and Johnson & Johnson as examples. Small-cap stocks like CTMX offer higher growth potential but carry significant risk with no approved drugs and substantial losses. Megacap stocks like JNJ provide stability, consistent revenue growth, and dividend payments, though with lower explosive upside potential. The choice depends on individual investment goals and risk tolerance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.